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Objectives This study sought to compare the renal clearance mechanisms of B-type natriuretic peptide (BNP) and amino
terminal pro-B-type natriuretic peptide (NT-proBNP).
Background The small molecular weight proteins (SMWPs) BNP and NT-proBNP both inversely correlate with glomerular fil-
tration rate (GFR). Whether this association is causal or confounding is unknown and has been the basis of
widespread speculation.
Methods We combined measurements of BNP and NT-proBNP concentrations in the renal arteries and veins of 165 sub-
jects undergoing renal arteriography with invasive renal plasma flow (RPF) measurements and echocardiogra-
phy. Fractional extraction (FE) of BNP and NT-proBNP was computed.
Results The BNP and NT-proBNP concentrations correlated similarly to GFR (r  0.35 and r  0.30, respectively;
p  0.001 for both) but the NT-proBNP/BNP serum ratio was negatively associated with GFR (r  0.21,
p  0.008). Median FEBNP was 0.21 (interquartile range [IQR] 0.16 to 0.22) for left and 0.22 (IQR 0.17 to 0.29)
for right kidneys. Median FENT-proBNP was 0.16 (IQR 0.09 to 20) for left and 0.18 (IQR 0.12 to 0.22) for right kid-
neys. The FEBNP correlated with GFR (left: r  0.26, p  0.008; right: r  0.21, p  0.03) as did FENT-proBNP
(left: r  0.25, p  0.005; right: r  0.20, p  0.02). Although FEBNP and FENT-proBNP correlated strongly with
each other (left: r  0.66; right: r  0.60; p  0.001 for both), left and right FENT-proBNP/BNP ratios were not influ-
enced by GFR (r  0.10, p  0.30 and r  0.08, p  0.43, respectively). Multivariate analyses confirmed that
FE was not independently associated with BNP or NT-proBNP concentrations.
Conclusions Contrary to widespread belief (but in line with the renal physiology of SMWP), BNP and NT-proBNP are equally
dependent on renal function for their clearance. (J Am Coll Cardiol 2009;53:884–90) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.11.032w
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ardiovascular medicine. Both the diagnostic accuracy as
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ccepted November 16, 2008.ell as the prognostic value of these peptides have been
stablished in patients across the spectrum of cardiovascular
iseases, from apparently well patients to those with end-
tage heart failure (1–5).
See page 891
An important prerequisite for use of tests such as the
atriuretic peptides is a firm understanding of the physiol-
gy that affects their levels. Among the factors that are
nown to affect both peptides is renal function. Indeed,
espite widespread use of natriuretic peptide testing, there is
till great uncertainty (and controversy) about the effect of
enal function on concentrations of both BNP and NT-
roBNP, and whether there is a difference between the 2
eptides in this regard (6,7).
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March 10, 2009:884–90 Equal Renal Clearance of BNP and NT-proBNPWhat is known at present is that observational studies
uggest that serum concentrations of BNP and NT-
roBNP are both inversely related to glomerular filtration
ate (GFR) (8 –10), and it has therefore been proposed
hat these peptides accumulate with declining GFR (9).
n addition, because the clearance of BNP also depends
n neutral endopeptidases and the type-C natriuretic
eptide receptor (11,12), the theory is that the NT-
roBNP concentration is more affected by renal clearance
han is BNP, a theory borne out by some studies
uggesting a steeper relationship between GFR and
T-proBNP concentrations compared with BNP, al-
hough not all studies confirm this finding (13–16).
On the other hand, it is well acknowledged that there is
strong direct interaction between abnormalities in the
ardiac and renal organ systems with prevalent cardiovascu-
ar disease among those with chronic kidney disease (CKD)
17,18). Thus, it has also been hypothesized that elevated
erum concentrations of natriuretic peptides in patients with
mpaired renal function may very well reflect increased
ardiac production because of cardiac dysfunction (19,20),
hich bears out their strong prognostic value in those with
KD (15,21).
Although these studies are of interest, they are all
bservational (and in most cases retrospective), rather than
irect examinations of mechanistic relationships between
enal function and both BNP and NT-proBNP. Given the
idespread and growing use of these peptides, it is clearly
ecessary at this juncture to move toward a physiologic,
echanistic understanding of this question. Prior studies
ooking at the dependence on renal clearance of BNP and
T-proBNP failed to show any difference between the 2
eptides (22–27), but these studies were small and often
ocused on only 1 of the 2 peptides. Accordingly, we
erformed a prospective, mechanistic study comparing in a
ead-to-head fashion the renal clearance of BNP and
T-proBNP in a large cohort of patients.
atients and Methods
atients. This study was performed in 165 hypertensive
atients in whom renal artery stenosis was initially suspected
n the basis of 1 or more of the following criteria:
reatment-resistant hypertension despite the use of at least 2
dequately dosed antihypertensive agents, overt peripheral
ascular disease, the presence of an abdominal bruit, or an
ncrease in serum creatinine during angiotensin-converting
nzyme inhibitor treatment. Patients in whom significant
enal artery stenosis was proven were not included in this
tudy. Written informed consent was obtained from all
atients, and the Medical Ethical Committee of the Maas-
richt University Hospital approved the study protocol. All
ntihypertensive medications were stopped 21 days before
he investigation.
echnical investigations. Before the administration ofodinated radiocontrast agents, simultaneous selective tatheterization of both renal ar-
eries and veins was performed,
ith blood samples drawn at
he same time for determina-
ion of BNP and NT-proBNP
oncentrations. The blood was
entrifuged immediately and
rozen at 80°C.
Subsequently, mean renal
lood flow (RBF) was measured
electively in both kidneys by the
33Xenon washout technique as
escribed (28–30), expressed as
l/min/100 g renal tissue.
Routine echocardiography (So-
os 5500, Hewlett Packard, An-
over, Massachusetts) was per-
ormed according to standard
linical protocol within the
-month period surrounding
ngiography. Left ventricular
ass index was determined by the formula from Devereux
t al. (31), left ventricular ejection fraction was calculated
sing end-diastolic volume and end-systolic volume mea-
urements from apical 4- and 2-chamber views calculated by
he Simpson method. Calculation of the diastolic filling
elocity (e velocity) and the peak filling velocity of early
trial contraction (a velocity) were used for the determina-
ion of the e/a ratio.
aboratory tests. The BNP concentrations were measured
sing an established radioimmunoassay method (Shionoria,
hionogi, Japan). The NT-proBNP concentrations were
etermined by an immunoelectrochemiluminescence method
Elecsys 2010, Roche Diagnostics, Basel, Switzerland).
reatinine concentrations were assessed by a modified
lkaline picrate method (Synchron LX 20, Beckman, Ful-
erton, California). The GFR was calculated using the
implified Modified Diet in Renal Disease formula (32).
alculations and statistics. The fractional extraction (FE)
f a molecule is the relative difference between the arterial
oncentration and the venous concentration of a molecule
ver a vascular bed or organ. Renal FE of substance X (FEx)
as calculated as [(arterial concentrationx – venous concen-
rationx)/arterial concentrationx]. The serum NT-proBNP/
NP ratio was computed by dividing the arterial NT-
roBNP concentration by the arterial BNP concentration.
he FENT-proBNP/BNP ratio in each kidney was defined by
ividing the FENT-proBNP by the FEBNP. Renal plasma flow
RPF) was calculated as: RBF  (1  hematocrit). Total
PF was calculated as the sum of left and right RPF.
For statistical analyses, SPSS 11.5 (SPSS Inc., Chicago,
llinois) software was used. Data are presented as medians
ith interquartile ranges (IQRs) for nonnormally distrib-
ted variables (identified when skewness was more than
ouble its standard error of the mean and compared using
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
CKD  chronic kidney
disease
FE  fractional extraction
GFR  glomerular filtration
rate
IQR  interquartile range
MAP  mean arterial
pressure
NT-proBNP  amino
terminal pro-B-type
natriuretic peptide
RBF  renal blood flow
RPF  renal plasma flow
SMWP  small molecular
weight proteinhe Mann-Whitney U test) and mean SD for all normally
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Equal Renal Clearance of BNP and NT-proBNP March 10, 2009:884–90istributed continuous variables, which were compared
sing analysis of variance. Pearson r (r) was used to test
orrelations when normally distributed. Non-normal vari-
bles were log-transformed and/or evaluated with Spearman
ho (rs), rather than Pearson r. The 2-tailed independent
tudent t test was used in normal distributed parameters,
nd the chi-square test was used for categorical variables.
ultivariable linear regression analyses identified indepen-
ent predictors of arterial BNP and NT-proBNP concen-
rations. Differences or correlations were considered signif-
cant when p  0.05.
esults
aseline characteristics. Renal angiography was success-
ully performed in all 165 subjects. Baseline characteristics
re shown in Table 1; 45 subjects (27%) had a GFR 60
l/min/1.73 m2. Compared with those with better renal
unction, subjects with a GFR 60 ml/min/1.73 m2 were
lder, had significantly lower RBF, e/a ratio, and hemato-
rit, and had higher NT-proBNP and BNP serum concen-
rations, whereas there were no significant differences in
ean arterial blood pressure (MAP) or left ventricular
jection fraction.
atriuretic peptide correlations. Serum concentrations
f BNP correlated directly with simultaneous values of
T-proBNP (r  0.79, p  0.001) (Fig. 1), whereas
orrelations between GFR and serum concentrations of
NP and NT-proBNP were significant, although less
obust (r  0.35 and r  0.30, respectively; p 
.001 for both).
enal clearance of BNP and NT-proBNP. Both left and
ight RPF correlated with GFR (rs  0.46 and rs  0.45,
espectively; both p  0.001). Despite the stronger corre-
ation between BNP and GFR, we did detect a small but
igher increase in NT-proBNP when GFR decreased,
aseline Characteristics of All Patients, Divided According to GFR
Table 1 Baseline Characteristics of All Patients, Divided Accor
GFR >60 ml/min/1.
(n  120)
Age (yrs) 54 12
Male sex, n (%) 64 (53)
Body mass index (kg/m2) 27 4
Mean arterial blood pressure (mm Hg) 133 22
e/a ratio 1.01 0.39
Left ventricular mass index (g/m2) 106 24
Left ventricular ejection fraction (%) 61 7
Serum BNP (pg/ml) 20 (9–40)
Serum NT-proBNP (pg/ml) 129 (44–220)
Serum creatinine (mol/l) 78 17
Hematocrit (%) 0.44 0.05
Left renal blood flow (ml/min/100 g) 203 68
Right renal blood flow (ml/min/100 g) 242 67
ata are given as mean  SD for parametric parameters and as median with interquartile range
BNP  B-type natriuretic peptide; GFR  glomerular filtration rate; NT-proBNP  amino termineflected by the negative correlation between the serumT-proBNP/BNP ratio and GFR (rs  0.21, p  0.008)
Fig. 2).
Median FEBNP was 0.21 (IQR 0.16 to 0.22) for left
idneys and 0.22 (IQR 0.17 to 0.29) for right kidneys (p 
.43). As shown in Table 2, FEBNP correlated with GFR in
oth left and right kidneys (rs  0.26, p  0.008 in left
idneys and rs  0.21, p  0.03 in right kidneys). The
edian FENT-proBNP was 0.16 (IQR 0.09 to 0.20) for left
idneys and 0.18 (IQR 0.12 to 0.22) for right kidneys (p 
.07). The FENT-proBNP correlated with GFR in both
idneys as well (left: rs  0.25, p  0.005; right: rs  0.20,
 0.02) (Figs. 3A and 3B).
To compare the renal clearances of BNP and NT-proBNP,
e looked at the association between FE of both peptides
ithin the same kidney. The FEBNP and FENT-proBNP corre-
ated highly in the left kidney as well as in the right kidney
to GFR
GFR <60 ml/min/1.73 m2
(n  45) p Value
62 10 0.001
18 (40) 0.26
27 5 0.51
139 26 0.17
0.79 0.22 0.002
116 34 0.09
61 10 0.95
65 (26–159) 0.001
473 (173–1,266) 0.001
131 55 0.001
0.41 0.07 0.006
147 66 0.001
182 44 0.001
parametric parameters.
-type natriuretic peptide.
Figure 1 Correlation Between Log-Transformed Serum
Concentrations of BNP or NT-proBNP and GFR
Open dots indicate BNP; solid dots indicate NT-pro-BNP. BNP  B-type natri-
uretic peptide; GFR  glomerular filtration rate; NT-proBNP  amino terminal
pro-B-type natriuretic peptide.ding
73 m2
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March 10, 2009:884–90 Equal Renal Clearance of BNP and NT-proBNPrs  0.66 and rs  0.60, respectively; p  0.001 for both). In
ddition to study differences in changes in FE possibly related
o GFR, we calculated the FENT-proBNP/BNP ratio in each
idney. The median FENT-proBNP/BNP ratio was 0.69 (IQR
.52 to 0.95) in the left kidney and 0.77 (IQR 0.61 to 1.00) in
he right kidney. Both the left FENT-proBNP/BNP ratio and the
ight FENT-proBNP/BNP ratio did not correlate with GFR, as
hown in Table 2 and Figure 4 (rs  0.10, p  0.30 and
s  0.08, p  0.43, respectively).
rediction of natriuretic peptide concentrations. Although
nivariate analyses showed a correlation between natriuretic
eptide levels and FEs or RPF, multivariate analyses
howed that FEBNP and FENT-proBNP were not independent
redictors of serum concentrations of these peptides (Table 3).
owever, left ventricular mass index, MAP, and GFR
ndependently predicted both peptides, whereas RPF inde-
endently predicted BNP values and showed a strong trend
n predicting NT-proBNP concentrations. The GFR was
lightly more strongly associated with NT-proBNP than
NP levels, but RPF was a stronger predictor for BNP
oncentrations.
iscussion
n this study, we prospectively compared the renal clearance
f BNP and NT-proBNP in 165 hypertensive subjects. We
Figure 2 Correlation Between the Serum
Ratio NT-proBNP/BNP and GFR
Abbreviations as in Figure 1.
orrelations Between GFR and FEs
Table 2 Correlations Between GFR and FEs
Spearman Correlation
Coefficient, r p Value
Left FEBNP 0.26 0.008
Right FEBNP 0.21 0.03
Left FENT-proBNP 0.25 0.005
Right FENT-proBNP 0.20 0.02
Left FENT-proBNP/BNP ratio 0.10 0.30
Right FENT-proBNP/BNP ratio 0.08 0.43E  fractional extraction; other abbreviations as in Table 1.ound that both BNP and NT-proBNP are indeed cleared
y the kidneys in a moderate fashion, yet interestingly and
mportantly, we found an equal dependence on renal clearance
or both peptides across the range of renal function examined
n this study. These results, generated from a mechanistic
ather than observational fashion, are robust evidence contra-
Figure 3 Correlations Between Fractional Extraction
and GFR in the Left and the Right Kidney
The correlation between fractional extraction and GFR for BNP (A) and
NT-proBNP (B). Solid dots indicate left kidney, open dots indicate right kidney.
Abbreviations as in Figure 1.
Figure 4 Correlation Between the Ratios of FENT-proBNP/BNP
in the Left and the Right Kidney With GFR
Solid dots indicate left kidney, open dots indicate right
kidney. FE  fractional extraction; other abbreviations as in Figure 1.
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Equal Renal Clearance of BNP and NT-proBNP March 10, 2009:884–90icting prevalent notions about a difference between BNP and
T-proBNP regarding their renal handling (6,14).
Considering the problem from a more scientific point of
iew, our results may not be surprising, although our data
re in stark contrast to what is currently accepted in the
iterature based on causal assumptions. Indeed, based on
heir molecular weight, both BNP (3.5 kDa) and NT-
roBNP (8.5 kDa) are by definition small molecular weight
roteins (SMWPs), which includes all proteins with a
olecular weight ranging from 1 to 50 kDa (33–35). The
MWPs are filtered relatively freely by the glomeruli and
atabolized by tubular epithelial cells without any other
rocessing such as tubular secretion as in creatinine (0.1
Da) or active reabsorption and return in the circulation as
or albumin (69 kDa). The FE of a SMWP is mostly
etermined by its molecular weight, whereas steric and
lectrostatic factors also may play a role (34). When filtration
s not influenced at all, the FE equals the filtration fraction,
hich is usually in the range of 0.20 to 0.25 in healthy subjects
23,36,37), and is approximated by the FEs we found. Lending
urther credibility to our results, based on the available theo-
etical models for renal SMWP clearance, a prior hypothetical
nivariate Analysis of Correlations Between Serumoncentrations of BNP r NT-proBNP Versusiochemical, Demographic, Renal, andchocardiographic Parameters
Table 3
Univariate Analysis of Correlations Between Serum
Concentrations of BNP or NT-proBNP Versus
Biochemical, Demographic, Renal, and
Echocardiographic Parameters
BNP NT-proBNP
Univariate Multivariate Univariate Multivariate
Age r 0.22 r 0.17
p 0.02 p 0.08
Body mass index r0.10 r0.11
p 0.19 p 0.16
MAP rs 0.31 t 2.03 rs 0.39 t 2.98
p 0.001 p 0.04 p 0.001 p 0.004
Hematocrit rs0.21 rs0.20
p 0.009 p 0.01
GFR r0.35 t 3.14 r0.30 t3.85
p 0.001 p 0.002 p 0.001 p 0.001
Left RPF rs0.31 rs0.24
p 0.001 p 0.001
Right RPF rs0.42 rs0.40
p 0.001 p 0.001
Total RPF rs0.38 t2.26 rs0.32 t1.86
p 0.001 p 0.02 p 0.001 p 0.07
Left FE rs0.28 rs0.19
p 0.004 p 0.04
Right FE rs0.26 rs0.16
p 0.009 p 0.08
LVEF rs0.20 rs0.24
p 0.02 p 0.007
LVMI rs 0.42 t 3.23 rs 0.48 t 4.00
p 0.001 p 0.002 p 0.001 p 0.001
e/a ratio rs0.28 rs0.28
p 0.001 p 0.001
E  fractional extraction; LVEF  left ventricular ejection faction; LVMI  left ventricular mass
ndex; MAPmean arterial pressure; RPF renal plasma flow; other abbreviations as in Table 1.tudy suggested that if clearance was purely based on molecular meight, filtration of BNP molecules would be 1.34 to 1.50
imes that of NT-proBNP, which is strikingly consistent with
he median FENT-proBNP/BNP ratios of 0.69 and 0.77 we
escribed (38). In addition, the FENT-proBNP/BNP ratios did
ot correlate with GFR, which indicates that the renal clear-
nce of both molecules is equally influenced by renal function.
Renal clearance of a molecule is defined by the FE of the
olecule and the RPF of the subject who is clearing the
olecule; the latter parameter resembles the proportion of
he circulating volume that is directed to the kidneys to be
leared in the manner as determined by the FE. Naturally,
PF is a factor that all molecules that are renally cleared
ave in common. In our multivariate analyses, FE was not
hown to be an independent predictor of serum levels of
NP and NT-proBNP, whereas left ventricular mass index,
AP, GFR, and RPF were found to be independently related
o BNP and NT-proBNP concentrations. Although, as men-
ioned previously, caution is needed when concluding causality
erely based an associations, the independent association with
PF might (partially) reflect the molecular nonspecific part of
he clearance, whereas left ventricular mass index may reflect
ardiac production of BNP and NT-proBNP.
In sum, our data indicate that in most patients tested with
NP or NT-proBNP (described by those with a GFR 30
l/min/1.73 m2), serum concentrations of BNP and NT-
roBNP may be more determined by cardiac production
han renal clearance, but there is no difference in the renal
learance between the 2 peptides.
At the lowest extreme of renal function in our study, we
id observe an inverse correlation between the NT-
roBNP/BNP ratio and GFR, which may be suggestive of
difference in removal from the blood stream between these
peptides at a range of GFR below 30 ml/min/1.73 m2.
ndeed, also in our population, the NT-proBNP/BNP ratio
ncreased when GFR decreased, as previously shown by
thers (14,39). It is worthwhile to speculate about alterna-
ive possibilities that may cause this discrepancy, including
ncreased extrarenal clearance of BNP in the context of
eclining renal function; indeed, neutral endopeptidases
eem to accumulate in the context of renal failure (40),
hereas up-regulation of the type-C natriuretic peptide
eceptor has been observed in more advanced disease states
s well (41,42). Both would more reduce concentrations of
NP relative to NT-proBNP in this context, as has also
een suggested (43,44). In addition, as suggested in our
igure 2 but also by the same analyses by Vickery et al. (14)
nd Kemperman et al. (39), heteroskedasticity cannot be
uled out. However, rather than speculation, what is needed
ow is a mechanistic understanding regarding both the
hysiology of extrarenal clearance of BNP, as well as
T-proBNP.
While contradicting a widely held notion (albeit based on
bservational data) that BNP is less dependent than NT-
roBNP on renal function for removal from the circulation,
e concede that an important limitation of our study is that
ost subjects had a GFR 30 ml/min/1.73 m2. This may
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March 10, 2009:884–90 Equal Renal Clearance of BNP and NT-proBNPe germane; however, the great majority of patients reported
n studies of BNP or NT-proBNP have renal function
losely parallel to that in our study (1,2). Further, in studies
f patients across a much wider range of renal function,
orrelations between BNP and NT-proBNP remained
trong even down to the end stage of CKD (15,16).
nother limitation of our study is that we analyzed patients
ith hypertension, rather than patients with heart failure.
lthough other much smaller mechanistic studies were not
erformed in heart failure patients either (22–27), our data
ctually provide insight to the clearance of BNP or NT-
roBNP in a population of patients in which these pep-
ides have been suggested to be of value for detection of
ardiac structural abnormalities and provide prognostic
alue (45–47). The fact that BNP and NT-proBNP con-
entrations are higher in heart failure patients within the
ame range of GFR as our patients only strengthens the fact
hat these concentrations may reflect cardiac production
ather than impaired clearance. As the use of both BNP and
T-proBNP expands across the spectrum of the American
eart Association stages of heart failure (from “at risk” to
end stage”), our findings are of value and quite germane to
he application of these assays.
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